The letter also noted there is no scientific literature calling into question the safety of taurine and guarana, two ingredients often used in such drinks with other ingredients including caffeine.

This is all good news for Monster, as today’s trading showed. And there could be more to come — after all, on the morning of Oct. 22 the stock opened at $53.46, only to plunge 14.5% after FDA incident reports linked the drink to five deaths. Even after Tuesday’s rise, Monster’s stock is just under $52, still below that Oct. 22 opening price and well below the all-time highs above $70 reached earlier this year. As the Journal’s story noted, Goldman Sachs analyst Judy Hong thinks the worst fears for the company — from regulators, at least — won’t come to pass.

We view [the] FDA’s response as encouraging and generally in line with our view that any regulatory outcome is likely to be benign…We continue to believe the most likely outcome will be increased disclosure and strengthening labeling, which is unlikely to have a material financial impact.

About Stocks To Watch

Earnings reports, corporate strategies and analyst insights are all part of what moves stocks, and they’re all covered by the Stocks to Watch blog. We also look at macro issues, investor sentiments and hidden trends that are affecting the market. Stocks to Watch gives you the full picture of the U.S. stock markets, all day long.

The blog is written by Ben Levisohn, a former stock trader who has covered financial markets for the Wall Street Journal, Bloomberg and BusinessWeek.